Diabetes

Educational resources

Index image

Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes

Supported by an educational grant from Sanofi Ltd

This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd

Deep dive on DPP-4 inhibitors

Deep dive on DPP-4 inhibitors with a focus on Trajenta® (linagliptin)

Promotional material from Boehringer Ingelheim Limited

This eLearning module and the associated videos have been commissioned and funded by Boehringer Ingelheim. The module and associated videos contain promotional content. For UK healthcare professionals.
View Trajenta® (linagliptin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
PC-GB-104526 July 2021

Biosimilar insulin WPG

Guideline for the managed introduction of biosimilar basal insulin

Supported by an educational grant from Mylan

This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.